Respiratory Viral Infections-Focused Revelation Biosciences Turns To SPAC Deal For NASDAQ Debut

Benzinga

2021-08-31

Revelation Biosciences Inc is joining Petra Acquisition Inc (NASDAQ: PAIC) to create a NASDAQ-listed company with an enterprise value of $128 million.
The merger is expected to close in Q4 2021, and the combined company will be listed on NASDAQ under the ticker symbol REVB.
Revelation will pocket $73 million through the merger and use the money to advance REVTx-99, a nasal drop formulation designed to stimulate the innate immune system via TLR4-TRIF pathway agonism.
In a 48-subject phase 1 trial, Revelation linked REVTx-99 to increased intranasal levels of the cytokine IP-10.
Revelation identified IP-10 as the key cytokine of interest because it is upregulated in response to respiratory viral infection and linked to clinical efficacy in challenge studies.
With phase 1 proof-of-principle data in hand, Revelation is now gearing up for further development.
A 60-subject phase 2 influenza viral challenge study is slated to start in Q1 of 2022.
REVTx-99 is also in development to treat chronic nasal congestion, with a phase 1 trial set to start this year.
The same platform has generated a second, earlier-stage candidate, REVTx-200. Revelation sees the follow-up prospect as a way to improve the immune response to intramuscular vaccines.
Price Action: PAIC stock is up 0.05% at $10.06 during the market session on the last check Monday.

See more from Benzinga

Click here for options trades from Benzinga
Anixa Biosciences' CAR-T Therapy To Start Human Trial For Ovarian Cancer
See Why SmileDirectClub Stock Is Moving Higher On Monday

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2163835157"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2163835157\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2163835157?lang=zh_TW&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/D_6R2C2YWK7KWM_dMj8JJg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/JJRp0CpE07aNuqQKXe927Q--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/185cd1c4322f0bd9969d0ef76bf0d880","is_english":true,"pubTime":"2021-08-31 03:10","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2163835157","market":"us","top_or_hot":-1,"title":"Respiratory Viral Infections-Focused Revelation Biosciences Turns To SPAC Deal For NASDAQ Debut","media":"Benzinga","content":"<html><body><img height=\"400\" src=\"https://s.yimg.com/uu/api/res/1.2/cd6iqSfD25GBsCU.xPXTxA--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/Benzinga/185cd1c4322f0bd9969d0ef76bf0d880\" title=\"\" width=\"600\"/>\n<ul>\n<li><strong>Revelation Biosciences Inc</strong> is joining <strong><a href=\"https://laohu8.com/S/PAICW\">Petra Acquisition Inc</a></strong> (NASDAQ:<strong> </strong>PAIC) to create a NASDAQ-listed company with an enterprise value of $128 million. </li>\n<li>The merger is expected to close in Q4 2021, and the combined company will be listed on NASDAQ under the ticker symbol REVB.</li>\n<li>Revelation will pocket $73 million through the merger and use the money to advance REVTx-99, a nasal drop formulation designed to stimulate the innate immune system via TLR4-TRIF pathway agonism. </li>\n<li>In a 48-subject phase 1 trial, Revelation linked REVTx-99 to increased intranasal levels of the cytokine IP-10. </li>\n<li>Revelation identified IP-10 as the key cytokine of interest because it is upregulated in response to respiratory viral infection and linked to clinical efficacy in challenge studies. </li>\n<li>With phase 1 proof-of-principle data in hand, Revelation is now gearing up for further development. </li>\n<li>A 60-subject phase 2 influenza viral challenge study is slated to start in Q1 of 2022. </li>\n<li>REVTx-99 is also in development to treat chronic nasal congestion, with a phase 1 trial set to start this year.</li>\n<li>The same platform has generated a second, earlier-stage candidate, REVTx-200. Revelation sees the follow-up prospect as a way to improve the immune response to intramuscular vaccines. </li>\n<li><strong>Price Action:</strong> PAIC stock is up 0.05% at $10.06 during the market session on the last check Monday.</li>\n</ul>\n<p><strong>See more from Benzinga</strong></p>\n<ul>\n<li>Click here for options trades from Benzinga</li>\n<li>Anixa Biosciences' CAR-T Therapy To Start Human Trial For Ovarian Cancer</li>\n<li>See Why SmileDirectClub Stock Is Moving Higher On Monday</li>\n</ul>\n<p><i>© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.</i></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Respiratory Viral Infections-Focused Revelation Biosciences Turns To SPAC Deal For NASDAQ Debut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRespiratory Viral Infections-Focused Revelation Biosciences Turns To SPAC Deal For NASDAQ Debut\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga</strong><span class=\"h-time small\">2021-08-31 03:10</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><img height=\"400\" src=\"https://s.yimg.com/uu/api/res/1.2/cd6iqSfD25GBsCU.xPXTxA--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/Benzinga/185cd1c4322f0bd9969d0ef76bf0d880\" title=\"\" width=\"600\"/>\n<ul>\n<li><strong>Revelation Biosciences Inc</strong> is joining <strong><a href=\"https://laohu8.com/S/PAICW\">Petra Acquisition Inc</a></strong> (NASDAQ:<strong> </strong>PAIC) to create a NASDAQ-listed company with an enterprise value of $128 million. </li>\n<li>The merger is expected to close in Q4 2021, and the combined company will be listed on NASDAQ under the ticker symbol REVB.</li>\n<li>Revelation will pocket $73 million through the merger and use the money to advance REVTx-99, a nasal drop formulation designed to stimulate the innate immune system via TLR4-TRIF pathway agonism. </li>\n<li>In a 48-subject phase 1 trial, Revelation linked REVTx-99 to increased intranasal levels of the cytokine IP-10. </li>\n<li>Revelation identified IP-10 as the key cytokine of interest because it is upregulated in response to respiratory viral infection and linked to clinical efficacy in challenge studies. </li>\n<li>With phase 1 proof-of-principle data in hand, Revelation is now gearing up for further development. </li>\n<li>A 60-subject phase 2 influenza viral challenge study is slated to start in Q1 of 2022. </li>\n<li>REVTx-99 is also in development to treat chronic nasal congestion, with a phase 1 trial set to start this year.</li>\n<li>The same platform has generated a second, earlier-stage candidate, REVTx-200. Revelation sees the follow-up prospect as a way to improve the immune response to intramuscular vaccines. </li>\n<li><strong>Price Action:</strong> PAIC stock is up 0.05% at $10.06 during the market session on the last check Monday.</li>\n</ul>\n<p><strong>See more from Benzinga</strong></p>\n<ul>\n<li>Click here for options trades from Benzinga</li>\n<li>Anixa Biosciences' CAR-T Therapy To Start Human Trial For Ovarian Cancer</li>\n<li>See Why SmileDirectClub Stock Is Moving Higher On Monday</li>\n</ul>\n<p><i>© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.</i></p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/respiratory-viral-infections-focused-revelation-191029570.html\">Benzinga</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/respiratory-viral-infections-focused-revelation-191029570.html","article_id":"2163835157","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/D_6R2C2YWK7KWM_dMj8JJg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/JJRp0CpE07aNuqQKXe927Q--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/185cd1c4322f0bd9969d0ef76bf0d880"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2163835157","pubTimestamp":1630350629,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Revelation Biosciences Inc is joining Petra Acquisition Inc (NASDAQ: PAIC) to create a NASDAQ-listed","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"以呼吸道病毒感染为重点的启示生物科学转向SPAC交易纳斯达克首次亮相","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PAIC":0.6,"PAICU":0.9},"content_text":"Revelation Biosciences Inc is joining Petra Acquisition Inc (NASDAQ: PAIC) to create a NASDAQ-listed company with an enterprise value of $128 million. \nThe merger is expected to close in Q4 2021, and the combined company will be listed on NASDAQ under the ticker symbol REVB.\nRevelation will pocket $73 million through the merger and use the money to advance REVTx-99, a nasal drop formulation designed to stimulate the innate immune system via TLR4-TRIF pathway agonism. \nIn a 48-subject phase 1 trial, Revelation linked REVTx-99 to increased intranasal levels of the cytokine IP-10. \nRevelation identified IP-10 as the key cytokine of interest because it is upregulated in response to respiratory viral infection and linked to clinical efficacy in challenge studies. \nWith phase 1 proof-of-principle data in hand, Revelation is now gearing up for further development. \nA 60-subject phase 2 influenza viral challenge study is slated to start in Q1 of 2022. \nREVTx-99 is also in development to treat chronic nasal congestion, with a phase 1 trial set to start this year.\nThe same platform has generated a second, earlier-stage candidate, REVTx-200. Revelation sees the follow-up prospect as a way to improve the immune response to intramuscular vaccines. \nPrice Action: PAIC stock is up 0.05% at $10.06 during the market session on the last check Monday.\n\nSee more from Benzinga\n\nClick here for options trades from Benzinga\nAnixa Biosciences' CAR-T Therapy To Start Human Trial For Ovarian Cancer\nSee Why SmileDirectClub Stock Is Moving Higher On Monday\n\n© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}